Pediatric Acute Lymphoblastic Leukemia: Pathogenesis of ALL, Immunotherapy, Chimeric Antigen Receptor [CAR T-cell therapy] and Novel Therapies

Discover the definitive guide to Pediatric Acute Lymphoblastic Leukemia (ALL), exploring cutting-edge advancements in treatment and therapy. Pediatric Acute Lymphoblastic Leukemia: Pathogenesis of ALL, Immunotherapy, Chimeric Antigen Receptor (CAR T-cell therapy) and Novel Therapies delves into the intricate landscape of immunotherapy, focusing on innovative approaches like CAR T-cell therapy targeting CD19 and CD22. This comprehensive volume navigates through minimization of therapy side effects and maximization of therapeutic benefits, offering insights into bi-specific T-cell engagers and emerging CD47/SIRPa pathways. From the mechanisms of lymphoblast illness to differential antibody therapies and metabolic modulators, each chapter explores critical disease mechanisms and potential risk factors. Essential topics include stem cell transplants, monoclonal antibodies, and the latest in proteasome inhibitors and tyrosine kinase inhibitors. Whether detailing the role of gemtuzumab ozogamicin in conditioning or post-allogeneic HSCT, this book equips researchers, clinicians, and students with up-to-date protocols and global adoption insights. Pediatric Acute Lymphoblastic Leukemia is a pivotal resource, providing a profound understanding of current treatments and promising future directions in pediatric oncology.